<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168309</url>
  </required_header>
  <id_info>
    <org_study_id>Pro34034</org_study_id>
    <nct_id>NCT02168309</nct_id>
  </id_info>
  <brief_title>Oral Nifedipine Versus Oral Labetalol</brief_title>
  <official_title>Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's aim is to determine whether oral extended release nifedipine is superior to oral
      labetolol for the management of postpartum severe hypertension, specifically time to achieve
      goal blood pressure, and shortening hospital stay. Our hypothesis is that oral extended
      release nifedipine is superior to oral labetolol for achieving goal blood pressure in the
      postpartum period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension complicating pregnancy is common and, when uncontrolled, can have devastating
      consequences. While the true incidence of postpartum hypertension is unknown, blood pressure
      (BP) is known to initially decrease 48 hours following delivery then peak on postpartum days
      3-6, likely 45 from the mobilization of interstitial fluids following parturition.

      The American College of Obstetricians and Gynecologists (ACOG) recommends medical treatment
      of persistent postpartum hypertension, defined as systolic BP (SBP) ≥150 mmHg or diastolic BP
      (DBP) ≥100 mmHg, on two or more occasions 4-6 hours apart. Prior studies compared intravenous
      medications to intramuscular and immediate-release oral 50 medications in the treatment of
      postpartum hypertension. However, oral labetalol and oral extended release nifedipine are the
      most commonly used medications for post- partum hypertension, and their efficacy has not been
      directly compared.

      Our aim was to determine whether oral labetalol is associated with a shorter time to BP
      control compared to oral extended release nifedipine for management of persistent 55
      postpartum hypertension. Our primary outcome was time to sustained BP control defined as the
      absence of severe hypertension (SBP ≥160 mmHg or DBP ≥105 mmHg) for at least 12 hours.
      Secondary outcomes included postpartum length of stay, need for increased dosing, need for
      additional oral antihypertensive agents, and patient-reported side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication</measure>
    <time_frame>24 hours</time_frame>
    <description>Primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Length of Hospital Stay in Days</measure>
    <time_frame>0-10 days</time_frame>
    <description>Secondary outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Severe Postpartum Hypertension</condition>
  <arm_group>
    <arm_group_label>Labetalol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Labetalol 200mg PO BID starting dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nifedpine XL starting at dose 30mg PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol</intervention_name>
    <description>Titrate up for blood pressure control</description>
    <arm_group_label>Labetalol</arm_group_label>
    <other_name>Oral labetalol starting at dose 200mg PO BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Titrate up to achieve blood pressure control</description>
    <arm_group_label>Nifedipine</arm_group_label>
    <other_name>Oral nifedipine 30mg XL PO starting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years with the abililty to give informed consent

          -  Intrauterine pregnancy ≥ 32 weeks

          -  Postpartum

          -  Persistent postpartum blood pressures ≥ 160/105 on two or more occasions

          -  Primary obstetrician amenable to starting either study medication in the postpartum
             period

        Exclusion Criteria:

          -  Use of other oral antihypertensives concomitantly

          -  Known AV heart block

          -  HR &lt;60 or &gt;120

          -  Absolute contraindication to nifedipine or labetolol such as allergy

          -  Significant renal disease (Cr &gt;1.5 mg/dL)

          -  Heart failure

          -  Moderate persistent or severe asthma

          -  Preexisting diagnosis of chronic hypertension with medical treatment before delivery

          -  Chronic hypertension
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Kilpatrick</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <results_first_submitted>April 27, 2017</results_first_submitted>
  <results_first_submitted_qc>November 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Sarah Kilpatrick</investigator_full_name>
    <investigator_title>Chair, Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Labetalol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Labetalol</title>
          <description>Labetalol 200mg PO BID starting dose
Labetalol: Titrate up for blood pressure control</description>
        </group>
        <group group_id="P2">
          <title>Nifedipine</title>
          <description>Nifedpine XL starting at dose 30mg PO daily
Nifedipine: Titrate up to achieve blood pressure control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Labetalol</title>
          <description>Labetalol 200mg PO BID starting dose
Labetalol: Titrate up for blood pressure control</description>
        </group>
        <group group_id="B2">
          <title>Nifedipine</title>
          <description>Nifedpine XL starting at dose 30mg PO daily
Nifedipine: Titrate up to achieve blood pressure control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="7.4"/>
                    <measurement group_id="B2" value="33.3" spread="6.4"/>
                    <measurement group_id="B3" value="33.7" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="4.1"/>
                    <measurement group_id="B2" value="33.0" spread="7.8"/>
                    <measurement group_id="B3" value="31.7" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication</title>
        <description>Primary outcome</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Labetalol</title>
            <description>Labetalol 200mg PO BID starting dose
Labetalol: Titrate up for blood pressure control</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>Nifedpine XL starting at dose 30mg PO daily
Nifedipine: Titrate up to achieve blood pressure control</description>
          </group>
        </group_list>
        <measure>
          <title>Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication</title>
          <description>Primary outcome</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="32.5"/>
                    <measurement group_id="O2" value="38.2" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Length of Hospital Stay in Days</title>
        <description>Secondary outcome</description>
        <time_frame>0-10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Labetalol</title>
            <description>Labetalol 200mg PO BID starting dose
Labetalol: Titrate up for blood pressure control</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>Nifedpine XL starting at dose 30mg PO daily
Nifedipine: Titrate up to achieve blood pressure control</description>
          </group>
        </group_list>
        <measure>
          <title>Total Length of Hospital Stay in Days</title>
          <description>Secondary outcome</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.5"/>
                    <measurement group_id="O2" value="4.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Labetalol</title>
          <description>Labetalol 200mg PO BID starting dose
Labetalol: Titrate up for blood pressure control</description>
        </group>
        <group group_id="E2">
          <title>Nifedipine</title>
          <description>Nifedpine XL starting at dose 30mg PO daily
Nifedipine: Titrate up to achieve blood pressure control</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathryn Sharma</name_or_title>
      <organization>Central Coast Perinatology</organization>
      <phone>8058980258</phone>
      <email>katy.jones@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

